Antibody-drug conjugates in breast cancer: current evidence and future directions
Authors:
Open Access
- 20 March 2025
- journal article
- review article
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 14 (1) , 1-19
Abstract
Antibody-drug conjugates (ADCs) are a rapidly evolving class of antitumor drugs and have already revolutionized the treatment strategy of many hematologic and solid cancers. So far, trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) are the four ADCs that have been approved by US food and drug administration (FDA) in treatment of breast cancer, and SKB264 has been approved by Chinese national medical products administration (NMPA). Many ADCs for treatment of breast cancer are currently being tested in late-phase clinical trials, with several encouraging results achieved recently. However, major issues arise during the use of ADCs, including emergence of acquired resistance, occurrence of treated-related toxicities, and identification of biomarkers of response and resistance. ADCs are being increasingly tested in combination with other agents, and novel next-generation ADC development is progressing rapidly. A better understanding of the design and development of ADCs will promote ADC development for cancer treatment. In this review, we aim to provide a broad overview of the design and the recent advances of ADCs in breast cancer. We also propose several notable future directions of ADCs in treatment of breast cancer.Keywords
Funding Information
- the Basic and Applied Basic Research Foundation of Guangdong province (2024A1515030227)
This publication has 136 references indexed in Scilit:
- Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib studyCancer Communications, 2024
- The safety of trastuzumab deruxtecan (DS‐8201) with a focus on interstitial lung disease and/or pneumonitis: A systematic review and single‐arm meta‐analysisCancer, 2024
- A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatmentsInternational Journal of Cancer, 2023
- Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysisCancer, 2022
- Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutionsCancer Communications, 2022
- Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug ConjugatesJAMA Oncology, 2021
- Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast CancerJAMA Oncology, 2021
- Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I studyCancer Communications, 2021
- Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNECancer, 2019
- Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapyBreast Cancer Research and Treatment, 2018